Reviewed by Michael Gill, B. Sc.
25 Rheumatoid Arthritis Clinical Trials Near Me
Top Hospitals for Rheumatoid Arthritis Clinical Trials
Image of Altoona Center for Clinical Research in Pennsylvania.
Altoona Center for Clinical Research
Duncansville
8Active Trials
62All Time Trials for Rheumatoid Arthritis
2002First Rheumatoid Arthritis Trial
Image of West Tennessee Research Institute in Tennessee.
West Tennessee Research Institute
Jackson
5Active Trials
26All Time Trials for Rheumatoid Arthritis
2007First Rheumatoid Arthritis Trial
Top Cities for Rheumatoid Arthritis Clinical Trials
Rheumatoid Arthritis Clinical Trials by Phase of Trial
Phase 1 Rheumatoid Arthritis Clinical Trials
10Active Rheumatoid Arthritis Clinical Trials
10Number of Unique Treatments
57Number of Active Locations
JNJ-67484703Sofusa DoseConnectMultiSpectral Imaging SystemCohort IIIIA-14069Cohort 12 million hMSC/kgPioglitazone
Rheumatoid Arthritis Clinical Trials by Age Group
18+ Rheumatoid Arthritis Clinical Trials
85Active Rheumatoid Arthritis Clinical Trials
RA Medication summary guide and RA ChoiceTherapeutic drug monitoring (TDM)KPL-404UpadacitinibJNJ-67484703MBSR treatmentActive stimulation QIDSofusa DoseConnect
Top Treatments for Rheumatoid Arthritis Clinical Trials
Treatment Name
Active Rheumatoid Arthritis Clinical Trials
All Time Trials for Rheumatoid Arthritis
First Recorded Rheumatoid Arthritis Trial
Upadacitinib
4
14
2014
Baricitinib
2
13
2007
Abatacept
2
54
2002
Filgotinib
2
13
2014
RA Medication summary guide and RA Choice
1
1
2022
Recently Completed Studies with FDA Approved Treatments for Rheumatoid Arthritis
Treatment
Year
Sponsor
Nipocalimab
2021
Janssen Research & Development, LLC
Certolizumab pegol
2021
UCB Biopharma SRL
LY3462817
2021
Eli Lilly and Company
PF-06650833
2020
Pfizer
csDMARDs
2019
GlaxoSmithKline
Methotrexate
2019
GlaxoSmithKline

What Are Rheumatoid Arthritis Clinical Trials?

Rheumatoid Arthritis clinical trials determine whether new treatments for Rheumatoid Arthritis are effective and well tolerated by patients.

The measurement of the success of a trial depends on an improvement in the patient's overall well-being and effective disease management. There must be an initial patient diagnosis and an endpoint to measure improvement from clinical trials. Rheumatoid Arthritis Severity Scale (RASS) Index measures symptoms based on disease activity, functional impairment, and physical damage.

Recent clinical trials aim to find a new-generation medication with fewer negative side effects than autoimmune suppressant treatments, as well as alleviation of symptoms, minimization of damage to joints, prolonged periods of remission, and increased joint mobility.

Why Is Rheumatoid Arthritis Being Studied Through Clinical Trials?

Rheumatoid Arthritis is an autoimmune disease resulting in painful, inflamed joints which may become deformed over time. An autoimmune disease is defined by the body attacking its healthy cells, and in the case of Rheumatoid Arthritis, the body attacks healthy tissue.

Rheumatoid Arthritis first manifests in smaller joints, such as fingers and toes, and gradually progresses to larger ones, like knees, elbows, hips, ankles, and shoulders. The disease has stages of flare-ups and remission. Inflammation generally appears on both sides of the body.

Not only does Rheumatoid Arthritis affect joints, but it may also cause other health concerns and damage to the heart, lungs, eyes, kidneys, nerves, and nerve tissues.

What Are The Types of Treatments Available For Rheumatoid Arthritis?

Various treatments are available for Rheumatoid Arthritis ranging from over-the-counter medication to surgery in extreme cases. The nature of the treatment depends on the severity and impact of the disease.

Treatments for Rheumatoid Arthritis are:

  • NSAIDs – Nonsteroidal Anti-inflammatory drugs bought which do not require a prescription from a medical practitioner and help reduce pain and inflammation.
  • Steroids – Corticosteroids reduce inflammation and slow damage to the joints.
  • DMARDs – Disease-Modifying Antirheumatic drugs are a conventional treatment and prevent permanent damage to the joints and include Trexall, Otrexup, Arava, Plaquenil, and Azulfidine.
  • Targeted DMARDs – These drugs are used when none of the other available medications provide no improvement to symptoms.
  • Biologic Agents – These are new drugs, also known as Biologic Response Modifiers, such as Humira, Orencia, Kineret, Cimzia, and others.

Surgery is an option when Rheumatoid Arthritis causes severe pain and significantly reduces mobility. Typical surgeries include the removal of the inflamed lining of the joint (Synovectomy), tendon repair, fusing joints, and joint replacement.

What Are Some Recent Breakthrough Clinical Trials For Rheumatoid Arthritis?

2022: Janus Kinase (JAK) inhibitors, Rinvoq, Olumiant, and Xeljanz, treat Rheumatoid Arthritis by blocking Janus Kinase enzymes which provide pathways for pro-inflammatory cytokines to be released into the body. These drugs are DMARDs and assist in slowing the long-term degeneration effects of the disease.

2022: Otilimab is a new market injectable and a monoclonal antibody that suppresses the inflammatory cytokine GM-CSF. The significance of this breakthrough clinical trial is that Otilimab treats both inflammation and pain effectively, and patients do not need to add pain medication to their treatment regime.

Who Are Some Of The Key Opinion Leaders In Psoriasis Clinical Trial Research?

Dr. Philip Mease has an internal medicine and fellowship in rheumatology at the University of Washington and is a Clinical Professor of Medicine. He leads rheumatology research at the Swedish Medical Center and has written 300 journal articles. He is a well-respected international speaker addressing medical conferences on rheumatology and dermatology.

Amye L. Leong, MBA, is the first person from the rheumatology community to receive the 2001 Presidents Service Award, the most prestigious community service award in America. Her credentials include Advisor to the US Food and Drug Administration, Patient-Centered Outcomes Research Institute, and Agency for Health Research and Quality. Her Patient Engagement Research has received 34 citations in journals reviewed by her peers.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 18th, 2021

Last Reviewed: October 25th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008 Jan;58(1):26-35. doi: 10.1002/art.23176. https://pubmed.ncbi.nlm.nih.gov/181634972 Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep;62(9):2569-81. doi: 10.1002/art.27584. https://pubmed.ncbi.nlm.nih.gov/208725953 Lorig K, Chastain RL, Ung E, Shoor S, Holman HR. Development and evaluation of a scale to measure perceived self-efficacy in people with arthritis. Arthritis Rheum. 1989 Jan;32(1):37-44. https://pubmed.ncbi.nlm.nih.gov/29124634 Yamaoka K, Tanaka Y, Kameda H, Khan N, Sasaki N, Harigai M, Song Y, Zhang Y, Takeuchi T. The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. Drug Saf. 2021 Jun;44(6):711-722. doi: 10.1007/s40264-021-01067-x. Epub 2021 May 27. https://pubmed.ncbi.nlm.nih.gov/340417025 Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003 Mar 11;107(9):1303-7. https://pubmed.ncbi.nlm.nih.gov/126289526 Takarada Y, Takazawa H, Sato Y, Takebayashi S, Tanaka Y, Ishii N. Effects of resistance exercise combined with moderate vascular occlusion on muscular function in humans. J Appl Physiol (1985). 2000 Jun;88(6):2097-106. https://pubmed.ncbi.nlm.nih.gov/108460237 Combe B, Besuyen R, Gómez-Centeno A, Matsubara T, Sancho Jimenez JJ, Yin Z, Buch MH. Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis. Rheumatol Ther. 2022 Oct 7. doi: 10.1007/s40744-022-00494-1. [Epub ahead of print] https://pubmed.ncbi.nlm.nih.gov/362059108 Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003 Mar 11;107(9):1303-7. https://pubmed.ncbi.nlm.nih.gov/126289529 Nader A, Mohamed MF, Winzenborg I, Doelger E, Noertersheuser P, Pangan AL, Othman AA. Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid Arthritis. Clin Pharmacol Ther. 2020 Apr;107(4):994-1003. doi: 10.1002/cpt.1671. Epub 2019 Nov 30. https://pubmed.ncbi.nlm.nih.gov/3161002110 Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998 May;41(5):778-99. https://pubmed.ncbi.nlm.nih.gov/9588729